The aim of this study was to investigate the buffering effect of a calcium glycerophosphate-fluoride (CaGP-F) dentifrice on in vivo dental biofilm after a cariogenic challenge and evaluate its probable 12-hour protective effect. Twelve young adults took part in this randomized, double blind, 14-day 4-phase crossover study. Between each phase, the volunteers had a 1-week wash-out period. Coded dentifrices were randomly assigned to the volunteers: A) no F and no CaGP; B) CaGP-only (0.13%); C) F-only (1500 ppm (ppm= parts per million of fluoride which is equivalent to mg/kg)); D) CaGP-F (0.13%, 1500 ppm, respectively). The pH measurements were taken from a single-site using a microelectrode, with salt bridge established by a 1M KCl (one molar potassium chloride) solution with a reference electrode. pH measurements were taken at 0 (baseline), 1, 7, 14 and 21 min (minutes) after a cariogenic challenge (10% w/v sucrose solution, %w/v = percent weight per volume). Four sets of measurements were carried out: (D0BS) before test dentifrice usage; (D01min) 1-min after test dentifrice usage; and (D712h) 7 days and (D1412h) 14 days using the test dentifrice, 12 hours (h)after brushing. Stephen curves and mean AUC (area under the curve) were obtained.

Start Date01 Jan 2006

Sponsor / Collaborator

Universidade Federal da Paraíba

[+1]

CTRI/2009/091/000924 / CompletedNot Applicable

A comparison of anticaries and antiplaque efficacy of a fluoridated dentifrice containing 1000 ppm sodium monofluoro phosphate + calcium glycerophosphate and non fluoridated dentifrice: a one and a half year clinical trial

Start Date18 Jan 2005

Sponsor / Collaborator-

100 Clinical Results associated with Calcium Glycerophosphate

100 Translational Medicine associated with Calcium Glycerophosphate

100 Patents (Medical) associated with Calcium Glycerophosphate

973

Literatures (Medical) associated with Calcium Glycerophosphate

01 Dec 2024·International Journal of Pharmaceutics

Erlotinib and curcumin-loaded nanoparticles embedded in thermosensitive chitosan hydrogels for enhanced treatment of head and neck cancer

Article

Author: Ezzat, Helal ; Ali Alghamdi, Maha ; Najm, Muna B. ; Greish, Khaled ; Jagal, Jayalakshmi ; Najm, Muna B ; Haider, Mohamed ; Haider, Youssef ; Jayakuma, Manju N. ; Hassan, Hatem A F M ; Hassan, Hatem A.F.M. ; Jayakuma, Manju N

Head and neck squamous cell carcinoma (HNSCC) remain a major oncological challenge with significant morbidity and mortality rates. Erlotinib (Er) and Curcumin (Cm) are potential therapeutic agents for HNSCC, yet they are hindered by poor solubility and bioavailability. This study explored the optimization of poly(lactic-co-glycolic acid) nanoparticles co-loaded with Er and Cm (Er/Cm-NP), prepared via a D-optimal response surface design-guided nanoprecipitation process. The optimized formulation, optEr/Cm-NP, was then incorporated into chitosan/β-glycerophosphate hydrogels (optEr/Cm-NP-HG) to create an injectable intratumoral (IT) nanocomposite hydrogel (HG) delivery system. Physicochemical properties of the formulations, including gelation time, injectability, mechanical strength and drug release profiles were assessed alongside hemolytic activity. Compared to optEr/Cm-NP alone, the NP-loaded HG formulation exhibited a more pronounced modulation effect, enabling sustained and controlled drug release. The cytotoxicity of the developed formulations was evaluated using the FaDu HNSCC cancer cell line. Both optEr/Cm-NP and optEr/Cm-NP-HG21 displayed enhanced cytotoxicity compared to free drugs. Confocal laser microscopy and flow cytometry confirmed superior cellular uptake of Er and Cm when delivered via NPs or NP-loaded HG. Furthermore, a significant increase in apoptotic cell death upon treatment with optEr/Cm-NP was observed, highlighting its potential for HNSCC therapy. In vivo studies conducted on a xenograft HNSCC mouse model revealed the significant capacity of the intratumorally-injected optEr/Cm-NP-HG21 formulation to retard the tumor growth. Conclusively, the results presented herein report the successful development of a nanocomposite HG system incorporating NPs co-loaded with Er and Cm that could be efficiently utilized in the treatment of HNSCC.

01 Oct 2024·Odontology

Biomineralization and remineralizing potential of toothpastes containing nanosized β-calcium glycerophosphate: an in vitro study

Article

Author: Nunes, Gabriel Pereira ; Rischka, Klaus ; de Camargo, Emerson Rodrigues ; Sousa, Yara Teresinha Correa Silva ; Danelon, Marcelle ; Gonçalves, Francyenne Maira Castro ; Delbem, Alberto Carlos Botazzo

To evaluate the effect of 1100 ppm F toothpastes supplemented with micrometric or nanosized β-CaGP (β-CaGPm/β-CaGPn) on artificial enamel remineralization, using a pH cycling model. Enamel blocks with artificial caries were randomly allocated into ten groups (n = 10), according to the toothpastes: without fluoride/β-CaGPm/β-CaGPn (negative control); 1100 ppm F (1100F); 1100F plus 0.125%, 0.25%, 0.5%, and 1.0% of β-CaGPm or β-CaGPn. The blocks were treated 2×/day with slurries of toothpastes. After pH cycling, the percentage of surface hardness recovery (%SH_R); integrated loss of subsurface hardness (ΔKHN); integrated mineral loss (ΔIMR); fluoride (F), calcium (Ca), and phosphorus (P) concentrations in the enamel; polydispersity index (PdI); and zeta potential (Zp) were determined. The data were analyzed by ANOVA (p < 0.001). For Zp/PdI, no significance was observed when comparing the means (p > 0.001). The treatment with 1100F-0.25%β-CaGPn led to %SH_R ∼57 higher when compared to the 1100F group (p < 0.001). The lowest ΔKHN was observed for the 1100F-0.25%β-CaGPn group (p < 0.001). The ΔIMR was lower (∼201%) for the 1100F-0.25%β-CaGPn when compared to 1100F (p < 0.001). The association of β-CaGPm and β-CaGPn to 1100F did not influence its F concentration (p > 0.001). The highest increase in Ca and P was observed for 1100F-0.25%β-CaGPn (p < 0.001). The addition of 0.25%β-CaGPn to 1100F toothpaste was able to promote an additional remineralizing effect of artificial caries lesions.

01 Oct 2024·International Journal of Biological Macromolecules

Chitosan/β-glycerophosphate porous microsphere prepared by facile water-in-water emulsion as a topical hemostatic material

Article

Author: Chi, Zhe ; Tian, Yu ; Ding, Yuanyuan ; Liu, Chenguang ; Yu, Lejun

Acute hemorrhage is a major cause of death in many emergency cases. Although many hemostatic materials have been studied in recent years, it is still necessary to develop new hemostatic materials with remarkable efficiency, biosafety, convenient preparation, low cost, and good biodegradability. In this work, novel chitosan (CS)/β-glycerophosphate (β-GP) composite porous microsphere with a uniform size of 210.00 ± 2.14 μm was fabricated through water-in-water (W/W) emulsion via microencapsulation, which can avoid the use of toxic crosslink chemicals and organic solvents to achieve facile and efficient preparation of microspheres. β-GP could promote the formation of microspheres by enhancing the hydrogen-bonding interaction between CS chains, which contributed to the macro-porous structure. Owing to their large pore size (6.0 μm) and high specific surface area (37.8 m²/g), the CS/β-GP microspheres could absorb water quickly and adsorb protein, red blood cells, and platelets through electrostatic forces to promote blood coagulation. Furthermore, the CS/β-GP microspheres achieved a significantly shortened hemostatic time (45 s) and reduced blood loss (0.03 g) in a rat liver injury model. Rat tail amputation test also showed a satisfactory hemostatic effect. Overall, the green and porous CS/β-GP microspheres can be used as a facile and topical rapid hemostatic material.

100 Deals associated with Calcium Glycerophosphate

External Link

KEGG	Wiki	ATC	Drug Bank
D01488	Calcium Glycerophosphate	A12AA08	DB11264

R&D Status

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Osteomalacia	-	-	-

Clinical Result

Indication

Phase

Evaluation

View All Results

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis